A. Galid

1.6k total citations
27 papers, 748 citations indexed

About

A. Galid is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Galid has authored 27 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Galid's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (5 papers). A. Galid is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (5 papers). A. Galid collaborates with scholars based in Austria, United States and Switzerland. A. Galid's co-authors include Michael Gnant, R. Jakesz, Brigitte Mlineritsch, Marianne Schmid, G. Luschin-Ebengreuth, Christian Menzel, H. Hausmaninger, S. Grampp, Martina Mittlboeck and Margaretha Rudas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

A. Galid

25 papers receiving 728 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Galid Austria 9 519 209 167 155 113 27 748
L.V.A.M. Beex Netherlands 14 573 1.1× 119 0.6× 177 1.1× 153 1.0× 67 0.6× 33 844
Sara Donati Italy 16 497 1.0× 220 1.1× 191 1.1× 103 0.7× 35 0.3× 40 756
Annalisa La Cesa Italy 14 459 0.9× 47 0.2× 142 0.9× 117 0.8× 142 1.3× 24 657
Leo V. Lacerna United States 10 734 1.4× 82 0.4× 254 1.5× 200 1.3× 361 3.2× 13 802
A Fontana France 10 324 0.6× 39 0.2× 89 0.5× 106 0.7× 128 1.1× 25 505
Yoo‐Joung Ko Canada 11 227 0.4× 153 0.7× 620 3.7× 92 0.6× 64 0.6× 23 901
Olga Venditti Italy 8 517 1.0× 117 0.6× 204 1.2× 115 0.7× 43 0.4× 26 786
Matthias Geberth Germany 11 437 0.8× 302 1.4× 232 1.4× 27 0.2× 26 0.2× 24 730
Allan Lipton United States 9 1000 1.9× 65 0.3× 249 1.5× 434 2.8× 197 1.7× 10 1.2k
Narciso Hernández Toriz Mexico 4 596 1.1× 59 0.3× 353 2.1× 168 1.1× 337 3.0× 6 799

Countries citing papers authored by A. Galid

Since Specialization
Citations

This map shows the geographic impact of A. Galid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Galid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Galid more than expected).

Fields of papers citing papers by A. Galid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Galid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Galid. The network helps show where A. Galid may publish in the future.

Co-authorship network of co-authors of A. Galid

This figure shows the co-authorship network connecting the top 25 collaborators of A. Galid. A scholar is included among the top collaborators of A. Galid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Galid. A. Galid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Singer, Christian F., Daniel Egle, Richard Greil, et al.. (2024). Abstract PO3-16-10: Real-world outcomes with first-line ribociclib + endocrine therapy in patients with metastatic HR+, HER2– breast cancer: Fourth interim analysis of REACH AUT trial. Cancer Research. 84(9_Supplement). PO3–16. 1 indexed citations
3.
4.
Singer, CF, Daniel Egle, Richard Greil, et al.. (2020). 172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC). Annals of Oncology. 31. S77–S78. 1 indexed citations
5.
Bjelic‐Radisic, Vesna, et al.. (2020). Fertilitätserhalt/Protektion bei Frauen mit Brustkrebs. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 17(4). 243–246. 1 indexed citations
6.
Kéilani, Mohammad, et al.. (2019). First exercise group for Turkish breast cancer patients in Vienna – a pilot project to include Turkish migrants. Disability and Rehabilitation. 42(1). 20–25. 8 indexed citations
7.
Bartsch, Rupert, Elisabeth Bergen, & A. Galid. (2018). Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. memo - Magazine of European Medical Oncology. 11(3). 199–203. 20 indexed citations
8.
Steger, Guenther G., Edgar Petru, Ferdinand Haslbauer, et al.. (2016). Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study. Annals of Oncology. 27. vi74–vi74. 2 indexed citations
9.
Petru, Edgar, Christian F. Singer, Stephan Polterauer, et al.. (2015). Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. Wiener Medizinische Wochenschrift. 165(19-20). 387–394. 4 indexed citations
10.
Bartsch, Rupert, Anna S. Berghoff, Ursula Vogl, et al.. (2015). Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clinical & Experimental Metastasis. 32(7). 729–737. 91 indexed citations
11.
Bartsch, Rupert, Anna S. Berghoff, Ursula Vogl, et al.. (2015). Abstract P6-16-10: Activity of T-DM1 in HER2-positive breast cancer brain metastases. Cancer Research. 75(9_Supplement). P6–16. 2 indexed citations
12.
Belle, Simon Van, et al.. (2011). Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy – data from the CHOICE study. Current Medical Research and Opinion. 27(5). 987–994. 5 indexed citations
13.
Memarsadeghi, Mazda, Christopher C. Riedl, A. Galid, et al.. (2006). Axillary Lymph Node Metastases in Patients with Breast Carcinomas: Assessment with Nonenhanced versus USPIO-enhanced MR Imaging. Radiology. 241(2). 367–377. 80 indexed citations
14.
15.
Hefler, Lukas, Christoph Grimm, A. Galid, et al.. (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecologic Oncology. 93(3). 686–690. 30 indexed citations
16.
Steger, Guenther G., E. Kubista, H. Hausmaninger, et al.. (2004). 6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. Journal of Clinical Oncology. 22(14_suppl). 553–553. 13 indexed citations
17.
Singer, Christian F., Gernot Hudelist, A. Galid, & E. Kubista. (2003). Pharmacological modulation of local feedback mechanisms as atherapeutic approach in breast cancer treatment. Drugs of today. 39(12). 917–917. 3 indexed citations
18.
Seifert, Michael, A. Galid, & E. Kubista. (2000). The oestrogen receptor and its selective modulators in gynaecological oncology. European Journal of Cancer. 36. 66–67.
19.
Seifert, Michael, A. Galid, & E. Kubista. (1999). Estrogen replacement therapy in women with a history of breast cancer. Maturitas. 32(2). 63–68. 9 indexed citations
20.
Seifert, Monika & A. Galid. (1998). Orale Kontrazeptiva und Brustkrebs – ein kausaler Zusammenhang?. Gyn�kologisch-geburtshilfliche Rundschau. 38(2). 101–104. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L.V.A.M. Beex Breakdown of academic impact, for papers by Sara Donati Breakdown of academic impact, for papers by Annalisa La Cesa Breakdown of academic impact, for papers by Leo V. Lacerna Breakdown of academic impact, for papers by A Fontana Breakdown of academic impact, for papers by Yoo‐Joung Ko Breakdown of academic impact, for papers by Olga Venditti Breakdown of academic impact, for papers by Matthias Geberth Breakdown of academic impact, for papers by Allan Lipton Breakdown of academic impact, for papers by Narciso Hernández Toriz
Rankless by CCL
2026